Velusetrag

Velusetrag (also known as TD-5108) is a serotonin receptor agonist developed by Theravance Biopharma for the treatment of gastrointestinal disorders. It is currently in clinical trials for the treatment of gastroparesis and chronic constipation.

History[edit | edit source]

Velusetrag was initially developed by Theravance Biopharma, a biopharmaceutical company focused on the creation of small molecule medicines. The drug is currently in the late stages of clinical trials.

Mechanism of Action[edit | edit source]

Velusetrag works by stimulating the 5-HT4 receptor, a type of serotonin receptor found in the gastrointestinal tract. This stimulation increases the movement of the intestines, helping to speed up the passage of food through the stomach.

Clinical Trials[edit | edit source]

Velusetrag has undergone several clinical trials for the treatment of gastroparesis and chronic constipation. In a Phase 2 trial, the drug was found to significantly improve gastric emptying and symptoms in patients with gastroparesis. A Phase 3 trial is currently underway.

Side Effects[edit | edit source]

Common side effects of Velusetrag include nausea, diarrhea, and headache. In clinical trials, these side effects were generally mild to moderate in severity.

Future Developments[edit | edit source]

If successful in clinical trials, Velusetrag could provide a new treatment option for patients with gastroparesis and chronic constipation, conditions for which there are currently limited treatment options.

Velusetrag Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.